Post-Herpetic Neuralgia Clinical Trial
Official title:
An Asian, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled 14-Week Study of DS-5565 in Patients With Post-herpetic Neuralgia Followed by a 52-Week Open-label Extension
NCT number | NCT02318719 |
Other study ID # | DS5565-A-J304 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | January 2015 |
Est. completion date | May 25, 2017 |
Verified date | October 2020 |
Source | Daiichi Sankyo, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Investigate the efficacy and safety of DS-5565 in subjects with Post-Herpetic Neuralgia (PHN) in comparison to placebo
Status | Completed |
Enrollment | 765 |
Est. completion date | May 25, 2017 |
Est. primary completion date | May 25, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years and older |
Eligibility | Inclusion Criteria: - PHN defined as pain present for more than 3 months after herpes zoster skin rash at screening - At screening, a pain scale of = 40 mm Exclusion Criteria: - Previous use of neurolytic block |
Country | Name | City | State |
---|---|---|---|
Japan | Medical Corporation Fujigaki Clinic | Oita |
Lead Sponsor | Collaborator |
---|---|
Daiichi Sankyo Co., Ltd. | Quintiles, Inc., SRL Medisearch Inc. |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in the Average Daily Pain Score (ADPS) From Baseline to Week 14 Following Oral Administration of DS-5565 in Asian Participants With Post-herpetic Neuralgia | Each participant recorded a pain score in the electronic patient diary once daily from the day after the screening visit (Visit 1) to the end of treatment/early termination visit (Visit 10). Prior to taking the study drug each morning, the participant selected the number that best described his or her pain over the past 24 hours on a scale of 0 (no pain) to 10 (worst possible pain). Higher ADPS scores indicated worse outcome. ADPS was the weekly average pain score based on the pain scores from the electronic patient diaries (Pain diary).
In this outcome, the change from baseline in ADPS is being reported with negative values representing improvements in average daily pain. The larger the negative value (ie. improvement), the greater the improvement in average daily pain. |
Baseline to Week 14 | |
Secondary | Change in Visual Analog Scale (VAS) Pain From Baseline (Week 14) to Week 66 Following Administration of DS-5565 in Asian Participants With Post-herpetic Neuralgia | Visual Analog Scale (VAS) pain is a 10-point assessment tool to measure pain levels, where 0 is defined as 'no pain' and 10 is defined as 'worst possible pain'. Higher VAS pain scores indicate worse outcome.
In this outcome, the change from baseline in VAS pain is being reported with negative values representing improvements in pain intensity. The larger the negative value (ie. improvement), the greater the improvement in pain intensity. |
From baseline (Week 14) to Week 66 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01944150 -
Association of Transcutaneous Electrical Nerve Stimulation and Hypnosis
|
N/A | |
Completed |
NCT00159666 -
Study of Pregabalin Therapy for Pain Relief in Subjects With Post-Herpetic Neuralgia
|
Phase 4 | |
Completed |
NCT00305357 -
Evolution of Pain From Herpes Zoster
|
||
Not yet recruiting |
NCT03120962 -
Effect of Early Use of Oxycodone During the Acute Phase of Herpes Zoster on Preventing Postherpetic Neuralgia
|
N/A | |
Completed |
NCT02701374 -
Efficacy and Safety of TRK-700 in Patient With Post-Herpetic Neuralgia
|
Phase 2 | |
Terminated |
NCT03094195 -
Dose Response Study of EMA401 in Patients With Post-herpetic Neuralgia (PHN)
|
Phase 2 | |
Completed |
NCT01752699 -
Methadone in Post-Herpetic Neuralgia Pain
|
Phase 3 | |
Completed |
NCT01250561 -
Reduction of Postherpetic Neuralgia in Herpes Zoster
|
N/A | |
Completed |
NCT02607280 -
DS-5565 Phase III Study for Renal Impairment in Japanese Subjects
|
Phase 3 | |
Completed |
NCT01037088 -
Effects of Vaporized Marijuana on Neuropathic Pain
|
Phase 1/Phase 2 | |
Completed |
NCT02633306 -
Transcranial Magnetic Stimulation for Facial Pain
|
N/A | |
Recruiting |
NCT05593237 -
Transcranial Magnetic Stimulation for Chronic Neuropathic Pain
|
N/A | |
Completed |
NCT01848730 -
Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Post-herpetic Neuralgia
|
Phase 2 |